Coya Therapeutics' (COYA) Buy Rating Reaffirmed at D. Boral Capital

Key Points

• Coya Therapeutics' stock received a "buy" rating reaffirmation from D. Boral Capital, with a target price of $18.00, indicating a potential upside of 209.70%.
• The company's recent quarterly earnings report showed a loss of ($0.36) per share, which was below analysts' expectations.
• Institutional investors hold 39.75% of the stock, with Northern Trust Corp increasing its stake by 12.2% in the last quarter.

Coya Therapeutics (NASDAQ:COYA - Get Free Report)'s stock had its "buy" rating reiterated by D. Boral Capital in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $18.00 price target on the stock. D. Boral Capital's target price suggests a potential upside of 209.70% from the stock's previous close.

COYA has been the subject of a number of other reports. HC Wainwright reaffirmed a "buy" rating and issued a $18.00 price objective on shares of Coya Therapeutics in a research note on Monday, August 25th. Chardan Capital reaffirmed a "buy" rating and issued a $14.00 price objective on shares of Coya Therapeutics in a research note on Wednesday, September 17th. Finally, Lake Street Capital initiated coverage on Coya Therapeutics in a research note on Wednesday, July 9th. They set a "buy" rating and a $16.00 target price for the company. Four research analysts have rated the stock with a Buy rating, According to data from MarketBeat, the company presently has an average rating of "Buy" and a consensus price target of $16.50.

Coya Therapeutics Stock Up 5.9%

NASDAQ:COYA opened at $5.81 on Monday. Coya Therapeutics has a 52 week low of $4.65 and a 52 week high of $10.24. The stock's fifty day moving average is $6.14 and its two-hundred day moving average is $5.99. The company has a market capitalization of $97.23 million, a P/E ratio of -4.71 and a beta of 0.26.

Coya Therapeutics (NASDAQ:COYA - Get Free Report) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.36) earnings per share for the quarter, missing analysts' consensus estimates of ($0.22) by ($0.14). The firm had revenue of $0.16 million during the quarter, compared to analyst estimates of $0.78 million. Sell-side analysts anticipate that Coya Therapeutics will post -1.15 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in COYA. Northern Trust Corp boosted its position in shares of Coya Therapeutics by 12.2% during the 4th quarter. Northern Trust Corp now owns 28,549 shares of the company's stock worth $164,000 after acquiring an additional 3,099 shares in the last quarter. Jane Street Group LLC purchased a new stake in shares of Coya Therapeutics in the 4th quarter valued at about $74,000. Dauntless Investment Group LLC purchased a new stake in shares of Coya Therapeutics in the 1st quarter valued at about $1,083,000. CM Management LLC lifted its holdings in shares of Coya Therapeutics by 25.0% in the 1st quarter. CM Management LLC now owns 200,000 shares of the company's stock valued at $1,294,000 after purchasing an additional 40,000 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. purchased a new stake in shares of Coya Therapeutics in the 1st quarter valued at about $65,000. 39.75% of the stock is owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.